Next Article in Journal
Impact of Malocclusion, Tooth Loss and Oral Hygiene Habits on Quality of Life in Orthodontic Patients: A Cross-Sectional Study
Next Article in Special Issue
Trends of Total Knee Arthroplasty According to Age Structural Changes in Korea from 2011 to 2018
Previous Article in Journal
Assessment of Referrals and Hospitalizations in the Hospital Transformed into COVID-19 Facility in Poland during the “Spring Wave” of the Epidemic in 2020—A Cross-Sectional Study
Previous Article in Special Issue
Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian Settings
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 18
Issue 13
10.3390/ijerph18137144
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study

by
Alessandra Mangia
1,
Francesco Scaglione
2,
Pierluigi Toniutto
3,
Mario Pirisi
4,
Nicola Coppola
5,
Giovanni Di Perri
6,
Gema Alvarez Nieto
7,
Stefano Calabrese
7,
Candido Hernandez
8,
Valentina Perrone
9,*,
Luca Degli Esposti
9 and
Stefano Fagiuoli
10 on the behalf of a LHUs Study Group
1
Liver Unit, Fondazione “Casa Sollievo Della Sofferenza” IRCCS, 71013 San Giovanni Rotondo, Italy
2
Department of Oncology and Onco-Hematology, University of Milan, 20122 Milan, Italy
3
Hepatology and Liver Transplantation Unit, Azienda Ospedaliero Universitaria, 33100 Udine, Italy
4
Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, 28100 Novara, Italy
5
Department of Mental Health and Public Medicine–Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Caserta, Italy
6
Department of Medical Sciences, University of Turin, 10124 Turin, Italy
7
Gilead Sciences, Medical Affairs Italy, 202124 Milan, Italy
8
Gilead Sciences, Global Medical Affairs, Stockley Park, London UB11 1BD, UK
9
CliCon S.r.l. Health, Economics & Outcomes Research, 40137 Bologna, Italy
10
Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(13), 7144; https://doi.org/10.3390/ijerph18137144
Submission received: 10 May 2021 / Revised: 25 June 2021 / Accepted: 25 June 2021 / Published: 3 July 2021
(This article belongs to the Special Issue Real-World Evidence in Clinical Epidemiology and Public Health)
Browse Figures
Versions Notes

Abstract

This Italian observational real-world study aims to assess in chronic hepatitis C virus (HCV) patients treated with pangenotypic direct acting agents (pDAAs) glecaprevir/pibrentasvir (GLE/PIB) or sofosbuvir/velpatasvir (SOF/VEL) the potential drug–drug interactions (DDIs) with concomitant medications prescribed, with a focus on cardiovascular and system nervous (CNS) co-medications. Data were collected from administrative databases covering 6.9 million health-assisted individuals. All patients prescribed SOF/VEL or GLE/PIB between 11/2017 and 12/2018 were included. Patients were analyzed while on DAA. DDIs were identified according to the Liverpool University tool. Overall, 3181 HCV patients were included: 1619 in the GLE/PIB cohort and 1562 in the SOF/VEL cohort. SOF/VEL patients were generally older than GLE/PIB ones (mean age 58.4 vs. 53.1, p < 0.001) and had more cardiovascular and CNS comorbidities (58% vs. 42%, p < 0.001 and 33% vs. 28%, p = 0.002, respectively). Contraindications due to DDIs in the GLE/PIB cohort affected 9.3% and 3.2% of patients before and on DAA, respectively, while the percentages in the SOF/VEL cohort were 3.2% before and 0.4% after pDAAs initiation. Among GLE/PIB patients, 2.7% had cardiovascular drugs (all statins) contraindicated while on DAA. The potential DDIs between cardiovascular drugs and SOF/VEL were mainly with statins (5%). SOF/VEL was prescribed in patients with older age and with more cardiovascular and CNS comorbidities. Despite this, a proportion of contraindicated drugs lower than that of GLE/PIB was registered.
Keywords: drug–drug interactions; glecaprevir/pibrentasvir; HCV; sofosbuvir/velpatasvir drug–drug interactions; glecaprevir/pibrentasvir; HCV; sofosbuvir/velpatasvir

Share and Cite

MDPI and ACS Style

Mangia, A.; Scaglione, F.; Toniutto, P.; Pirisi, M.; Coppola, N.; Di Perri, G.; Alvarez Nieto, G.; Calabrese, S.; Hernandez, C.; Perrone, V.; et al. Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int. J. Environ. Res. Public Health 2021, 18, 7144. https://doi.org/10.3390/ijerph18137144

AMA Style

Mangia A, Scaglione F, Toniutto P, Pirisi M, Coppola N, Di Perri G, Alvarez Nieto G, Calabrese S, Hernandez C, Perrone V, et al. Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. International Journal of Environmental Research and Public Health. 2021; 18(13):7144. https://doi.org/10.3390/ijerph18137144

Chicago/Turabian Style

Mangia, Alessandra, Francesco Scaglione, Pierluigi Toniutto, Mario Pirisi, Nicola Coppola, Giovanni Di Perri, Gema Alvarez Nieto, Stefano Calabrese, Candido Hernandez, Valentina Perrone, and et al. 2021. "Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study" International Journal of Environmental Research and Public Health 18, no. 13: 7144. https://doi.org/10.3390/ijerph18137144

APA Style

Mangia, A., Scaglione, F., Toniutto, P., Pirisi, M., Coppola, N., Di Perri, G., Alvarez Nieto, G., Calabrese, S., Hernandez, C., Perrone, V., Degli Esposti, L., & Fagiuoli, S., on the behalf of a LHUs Study Group. (2021). Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. International Journal of Environmental Research and Public Health, 18(13), 7144. https://doi.org/10.3390/ijerph18137144

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop